Kolon TissueGene (950160) Fundamentals 2026 — Revenue Analysis | SniperIQ
Kolon TissueGene (950160) is a US-listed Healthcare company in Biotechnology with a market capitalization of ₩2.55T, trading at ₩30050.00 on the KOE. This SniperIQ fundamentals page covers Kolon TissueGene's valuation, profitability (net margin -5479.6%), revenue (₩5.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kolon TissueGene's market cap?
Kolon TissueGene (950160) has a market capitalization of approximately ₩2.55T, trading at ₩30050.00 on the KOE. Market cap moves with the live share price.
What is Kolon TissueGene's P/E ratio?
Kolon TissueGene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 20.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kolon TissueGene?
Kolon TissueGene runs a net profit margin of -5479.6%, a gross margin of 13.2%, and an operating margin of -426.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kolon TissueGene generate?
Kolon TissueGene reported revenue of ₩5.2B for fiscal year 2025, with net income of -₩192.5B and earnings per share (EPS) of -2361.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kolon TissueGene pay a dividend?
Kolon TissueGene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Kolon TissueGene financially healthy?
Kolon TissueGene carries a debt-to-equity ratio of 0.52x and a current ratio of 0.33x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kolon TissueGene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kolon TissueGene (950160) the key facts are: market cap ₩2.55T, revenue ₩5.2B, 52-week range 30050-149000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kolon TissueGene's full fundamentals live
Get Kolon TissueGene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.